HIV Database Workshop www.hiv.lanl.gov seq-info@lanl.gov

Presenter: Brian Foley

Database PI: Brian Foley

Additional database staff: Werner Abfalterer, Katherine Belobrajdic, Elizabeth-Sharon Fung, Kumkum Ganguly, Bette Korber, Jennifer Macke, James Szinger, Hyejin Yoon







Theoretical Biology and Biophysics, T-6 Los Alamos National Laboratory

https://tinyurl.com/HIVDB-IEDB-2021



Workshop Topics


Introduction to HIV Sequence Database

HIV in comparison to other viruses

Exploration of HIV evolution, using one Gag epitope as an example.




Entry page at https://www.hiv.lanl.gov/




Questions or comments? Contact us at seq-info@lanl.gov





Operated by Triad National Security, LLC for the <u>U.S. Department of Energy's</u> National Nuclear Security Administration
<u>© Copyright Triad National Security, LLC. All Rights Reserved | Disclaimer/Privacy</u>





Questions or comments? Contact us at seq-info@lanl.gov.

• Los Alamos


					HI	V sequence dat	aDase
DATABASES	SEARCH	ALIGNMENTS	TOOLS	PUBLICATIONS	GUIDES	search site	Search
		Seque	ence Sea	arch Interface			
 The <i>italicized</i> To list fields t Use the + and 	fields are liste hat are not list - to see more alls about each	I name for specific tips to in output by default ted by default or included or fewer search fields field, see <u>Help</u> or <u>Data Dic</u>		put an asterisk (*) in the	input box	Last <u>GenBank</u> update: 2 <u>Advanc</u>	2021-09-20 <u>ed Search</u>
Upload acco	_	owse No file selecte	ed.				
<u>Sequer</u> <u>Sequer</u> exact ☑ <u>Samplin</u> ⊞ More sequer 3 Find all seq	nce information uences for a nic region 5'	a specific gene or reg ny mplete genome LTR	ion (HIV-1, S	SIVcpz and SIVgor) Or define <u>start</u> Include <u>fragments</u>	Subtype	Any subtype No subtype A A1 A2 A3 Include <u>recombinants</u>	
Combine da	5' 5' TA	ences with your own	sequence a	lignment (HIV-1, SIV	cpz and s	SIVgor)	
Patient Info Geographic Amino Acid Output	al Informati					•	
		lude <u>problematic</u> sequence ords per page	25	<u>% of</u> Show results set	non-ACGT	Show SQL	

Almost all of our pages, tools, etc. have help files explaining the uses and providing help.

Sample data sets to test each tool are also provided.

Each of these sections of the search interface are expandable to provide additional search capabilities.





 Heatmap displays a table of numbers by using colors to represent the numerical values

Hepitope identifies potential epitopes based on HLA frequencies

Neutralization Index computes a tier-like score for sera (using ID50 titers) or antibodies (using IC50 titers)

Mosaic Vaccine Tool Suite designs and assesses polyvalent protein sequences for T-cell vaccines

Some of our tools are specific to HIV or lentiviruses, most can be used on DNA or Protein sequences from any organism.

Color-coded square indicates whether a given tool is specific to HIV or not.

Tools are listed alphabetically and organized into general categories.

Write to <u>seq-info@lanl.gov</u> for additional help, or to report problems or suggest new tools or features.



<u>Alignment Slicer</u> cuts vertical slices from sequence alignments
 Analyze Align shows webloges, calculates frequency by position

Align Multi-tool manipulates sequence alignments, including

Alignment and sequence manipulation

sorting, pruning, and renaming

All viruses evolve, but each has unique influences on its epidemiology and evolution

HIV, HCV and some other viruses persist in one host individual long after immune response is mature. Can be passed to recipient individual after significant evolution/selection in donor individual.

Influenza viruses, coronaviruses, and many other viruses typically infect a naïve host individual and are rapidly passed on to next recipient individual before much host immune selection pressure has taken place.

HIV has been infecting humans for 100 years or more, and has relatively slowly spread around the world. HCV has been infecting humans for more than 20,000 years and likewise has spread quite slowly.

Influenza viruses and coronaviruses can spread around the world in a matter of weeks.



ing Filters					(human immur	nodeficiency virus 1 HIV-1) (ID:11676, human im	munodeficiency virus	HIV-1)
set Search	× Include	Positive Assays X No B cell assays	X No MHC ass	ays 🗙 Host: Homo sapiens (human)	1			
er Options (?)	Please s	ee HIV Molecular Immunolog	<u>y Databas</u>	e for more information.				
Cell ~		Epitopes (257)	Antigens (7)	Assa (892		Receptors (419)	Re	oferences (89)
				Go To Records St	arting At 120	00 💿		Export Results (
ope ?	257 Recon	ds Found		K K Page	of 11	> >1		25 YPer Pag
Any	Details •	✓ Epitope	*	Antigen	~	Organism	✓ # Referen	ices 🗸 # Assays 🐇
Linear peptide Length	59613	SLYNTVATL	7 ,	Gag polyprotein	Y .	Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)	7 26	56
Sequence Discontinuous	27125	ILKEPVHGV	7.	Gag-Pol polyprotein	7.	Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)	V 10	13
Non-peptidic	29804	KAFSPEVIPMF	7 4	Gag polyprotein	7.	Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)	₩ 8	30
3D structure available	33250	KRWIILGLNK	7.	Gag polyprotein	7.	Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)	7	15
no acid modification	127246	TSTLQEQIGW	Y .	Gag-Pol polyprotein	7 ,	Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)	7	11
ope Source (?	12616	EIYKRWII	7 ,	Gag polyprotein	7.	Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)	% 6	10
anism	102104	TAFTIPSI	7.	Gag-Pol polyprotein	7.	Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)	% 6	20
man immunodeficiency (1)	131070	SLFNTVATL	7 ,	Gag polyprotein	7 ,		% 6	17
core, capsid, myosin	1401	AFSPEVIPMFSALSEGATPQ	Y .	Gag-Pol polyprotein	7.		% 5	45
de related structure ct multiple options	29352	IVLPEKDSW	7.	Gag-Pol polyprotein	7.	,,	₹ 4	6
	56620	RYPLTFGWCF	7 4	Protein Nef	7.		V 4	19
•	59612	SLYNTIAVL	Y .	Gag-Pol polyprotein	Y ₄	Human immunodeficiency virus 1 (human	₹ 4	10
las TCR sequence	189277	SLFNTIAVL	7.	Gag polyprotein	7.	immunodeficiency virus 1 HIV-1) Human immunodeficiency virus 1 (human	V 4	16
Paired chains only	189288	SLYNTIATL	7 .	Gag-Pol polyprotein	7.		₩ 4	14
n Any Type 🗸	189293	SLYNTVAVL			7.		V 4	8
Exact Matche ~	21635	GPGHKARVL	7.	Gag polyprotein	7.	immunodeficiency virus 1 HIV-1) Human immunodeficiency virus 1 (human	% 3	7
I Assay (?)	28657	ISPRTLNAW	7.		7.	immunodeficiency virus 1 HIV-1)	₩ 3	3
come: Positive	32201	KLTPLCVTL	7.		7.	immunodeficiency virus 1 HIV-1)	V 3	14
iny	34482	KYKLKHIVW		Gag polyprotein	7.	immunodeficiency virus 1 HIV-1)	% 3	4
cytokine production	101990				7.	immunodeficiency virus 1 HIV-1)		
/IHC multimer	180191	QASQEVKNW	7.			Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)		6
Ex: IL-2 release Find		SLFNTIATL	7.		7.	immunodeficiency virus 1 HIV-1)	₩ 3	8
Pirect ex vivo detection	180236	SLFNTVAVL		Gag polyprotein	7.	immunodeficiency virus 1 HIV-1)	% 3	7
Restriction (?	1129	AEQASQDVKNW	Ÿ.	Gag polyprotein	Y ₄	Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)	2	4
ny	5295	AVDLSHFLK	7.	Protein Nef	7.	Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)	2	7
Class I Class II	9974	DRFYKTLRA	7.	Gag polyprotein	7.	Human immunodeficiency virus 1 (human immunodeficiency virus 1 HIV-1)	2	2

Searched the IEDB for CTL epitopes in HIV-1

Gag SLYNTVATL SLFNTVATL etc are found

How variable is this epitope in HIV-1?



DATABASES	SEARCH	ALIGNMENTS	TOOLS	PUBLICATIONS GUIDE	s search	site Search
			Index of all tools	Glycan Shield Mapping	Protein Feature Accent	
			Align Multi-tool	Heatmap	Quality Control	
		HIV	Alignment Slicer	Hepitope	QuickAlign	
			AnalyzeAlign	Highlighter	Rainbow Tree	
			AnnotateTree	HIV BLAST	RAPR	
Programs and			Branchlength	HIVAlign	Recombinant HIV-1 Drawing Tool	
earch Interface	retrieves HIV and	SIV sequences, which	CATNAP	Hypermut	RIP	publication
be aligned an	d used to build tr	ees	Codon Alignment	IQ-TREE	SeqPublish	ed content
Geography Search	h Interface retriev	ves HIV sequences base	c CombiNAber	jpHMM at GOBICS	Sequence Locator	
geographical			Consensus Maker	Mosaic Vaccine Tool Suite	SNAP	
Senome Browser	uses jBrowse to c and proteome	display diverse data ab	ELF	Motif Scan	SUDI Subtyping	
niv-i genome	and proteome		ElimDupes	N-Glycosite	SynchAlign	
	with sequences l	ists all our online tools	, Entropy	Neutralization Index	Translate	
by function			Epigraph	PCOORD	TreeMaker	
Alignments			FindModel	РерМар	TreeRate	
	nmonte includes (Consensus and Ancestra	Format Converter	PeptGen	Variable Region Cnaracteristics	
		Alignments, and Comp	Con Chain /Courseans	PhyloPlace	Variant Visualizer	
Alignments		· · · · · · · · · · · · · · · · · · ·	GenBank Entry Generation	PhyML	VESPA	
			Gene Cutter	Pixel	External Tools	
			Genome Browser	Poisson-Fitter		
1. Berner			GenSig	PrimerDesign-M		
New	24				Archived New	5
			No new new			

HIV Sequence Database Genome Browser

View genome or each protein to see features of interest

last modified: Tue Sep 7 15:54 2021

Questions or comments? Contact us at seq-info@lanl.gov.

Operated by Triad National Security, LLC for the <u>U.S. Department of Energy's</u> National Nuclear Security Administration © Copyright Triad National Security, LLC. All Rights Reserved | Disclaimer/Privacy







HIV sequence database





HIV Genome Browser

Purpose: Interactive view of the HIV genome and proteome for juxtaposition and exploration of multiple types of data. Help.

Starting Views

NOTE: These are just starting points! Within the genome browser, you can move among any of these views. Please read the quick tips and Help file before you start!

HIV-1 protein-level views:

• Env • Gag • Nef • Pol • Rev • Tat • Vif • Vpr • Vpu

- HIV-1 proteins, specific examples:
 - Env with CTL epitopes + entropy
 - Pol with drug resistance sites + entropy

Nucleotide-level views:

- HIV-1 gene map
- SIV Mac239 gene map
- HIV-1 5' LTR

Quick Tips

- Mouseovers! Look for mouseovers to guide you.
- Click and right-click! Features link to loads of information and analysis via click and right-click. If your mouse doesn't have right-click, use Ctrl-click.
- · Zoom! There are several ways to zoom in/out. Some features can only be seen when zoomed-in or zoomed-out.
- · For details about this interface, see HIV Genome Browser Help.
- · Watch the screencast video on the JBrowse website.


References

- Skinner ME, Holmes IH. Setting up the JBrowse genome browser. Curr Protoc Bioinformatics. 2010 Dec;Chapter 9:Unit 9.13.
 <u>PMID: 21154710</u>
- Skipper ME Uziley AV Stein LD Mungall CL Helmes H. Browkey a payt generation generation from the Conome Res 2000

HIV Genome Browser


Select Gag to see Gag protein view





Enter SLYNTVATL to zoom in to that site in the Gag protein.





HIV Genome Browser has tracks for entropy of each site

SLYNTVATL third amino acid, Y, has high entropy



н	I۱	m	

Databases	Search	Tools	Pro	ducts	Publicatio	ns	sea	arch site	Search	Site
				Sea	rch CTL/	CD8	8+ T-C	ell Ep	oitope	Data
<u>HIV protein</u>		- ALL - Gag p17 p24 p2p7p1p6								
HXB2 protein locat	tion					F	Results over	lap with q	uery locatio	n v
HXB2 DNA location	<u>1</u>					R	esults ove	rlap with	query loc	ation
<u>Epitope</u>		SLYNTVATL				F	Results con	ain query	sequence	~
Epitope name	[
Record number										
<u>Subtype</u>		- ALL -	~							
Immunogen		- ALL - computer predict engineered HIV-1 and HCV co HIV-1 exposed se HIV-1 infected mo HIV-1 infection	o-infectio ronegativ	/e						
		Vaccine type	ŀ	ALL -						~
Vaccine details		Vaccine strain	ŀ	ALL -		~				
if Immunogen is Va	accine	Vaccine compor	nent ·	ALL -	~					
		<u>Adjuvant</u>	ŀ	ALL -				~		
<u>Species</u>		- ALL -	~							
MHC/HLA		- ALL - A*01 A*01:01 A*01:23 A*02 A*02:01 A*02:02								
Author						C	First	ast		
Country		- ALL -		`	/					
<u>Keywords</u>		- ALL - acute/early infect adjuvant compari antagonism antibody binding antibody generati assay or method	son site on	nent						
		and a second	oph							


HIV Immunology Database CTL Search for SLYNTVATL

Search Reset Click for Search Help

Search CTL/CD8+ variants

Questions or comments? Contact us at immuno@lanl.gov





Notes

· Gag CTL response studied in three individuals.

human(C*14)


(MHC/HLA)

References

Johnson1991 R. P. Johnson, A. Trocha, L. Yang, G. P. Mazzara, D. L. Panicali, T. M. Buchanan, and B. D. Walker. HIV-1 Gag-Specific Cytotoxic T Lymphocytes Recognize Multiple Highly Conserved Epitopes. Fine Specificity of the Gag-Specific Response Defined by Using Unstimulated Peripheral Blood Mononuclear Cells and Cloned Effector Cells. J. Immunol., 147:1512-1521, 1991. This study presented a detailed study of gag-specific CTL from HIV-1 seropositive individuals. Seven p24 and two p17 epitopes were described, that were recognized by class I-restricted CD3+CD8+ CTL. p17 epitopes: KIRLRPGGKKKYKLKHIVWASRELE and QTGSEELRSLYNTVATLYCVHQRIE; p24 epitopes: NPPIPVGEIYKRWIILGLNKIV, VHQAISPRTLNAWVKVVEEKAF, NAWVKVVEEKAFSPEVIPMFSA, SALSEGATPQDLNTMLNTVGGH, GHQAAMQMLKETINEEAAEWDR, and RAEQASQEVK. PubMed ID: <u>1715361</u>. Show all entries for this paper.

301 Records found for SLYNTVATL in CTL epitopes

Each has a pre-done link to an analysis of diversity in sequence database alignment of one sequence per patient.





					HIV s	equence dat	abase
DATABASES	SEARCH	ALIGNMENTS	TOOLS	PUBLICATIONS	GUIDES	search site	Search
			Analy	zeAlign			
			/ indity.	Lernight			
Input options	maartad from O	uickAlign (6144 amin	a acid convor				
-		t results for all sequ					
Logo stack w		c results for all sequ	ences as a sin	gie group			
Stacks per li							
Units: proba							
Show x-axis:							
Show y-axis:							
	e: hydrophobicit	y					
	with largest let	·					
	bols from logo:						
Mark potent	ial N-linked glyc	osylation sites: no					
Delete gaps	and shift alignm	ent to C-terminus:	no				
Cut-off for c	alculating frequ	ency by position: 9	5%				

Warning: Your sequences had to be padded - please make sure all sequences are of the same length.



Master sequence for finding variants: SLYNSVATL

Download: PNG

Frequency by position


See full raw counts	
---------------------	--

full raw counts			cutoff: 95%
	Percentage and raw count of non-gap	Non-gap/total (percentage)	Gap/total (percentage)
S: 99.87% (6136)	other: 0.13% (8)	6144/6144 (100.00%)	0/6144 (0.00%)
L: 99.09% (6088)	other: 0.91% (56)	6144/6144 (100.00%)	0/6144 (0.00%)
F: 48.76% (2996)	Y: 46.88% (2880) other: 4.36% (268)	6144/6144 (100.00%)	0/6144 (0.00%)
N: 99.71% (6126)	other: 0.29% (18)	6144/6144 (100.00%)	0/6144 (0.00%)
T: 90.89% (5584)	A: 6.46% (397) other: 2.65% (163)	6144/6144 (100.00%)	0/6144 (0.00%)
V: 76.11% (4676)	I: 20.51% (1260) other: 3.39% (208)	6144/6144 (100.00%)	0/6144 (0.00%)
A: 90.53% (5562)	V: 8.61% (529) other: 0.86% (53)	6144/6144 (100.00%)	0/6144 (0.00%)
T: 70.17% (4311)	V: 29.30% (1800) other: 0.54% (33)	6144/6144 (100.00%)	0/6144 (0.00%)
L: 99.06% (6086)	other: 0.94% (58)	6144/6144 (100.00%)	0/6144 (0.00%)
	S: 99.87% (6136) L: 99.09% (6088) F: 48.76% (2996) N: 99.71% (6126) T: 90.89% (5584) V: 76.11% (4676) A: 90.53% (5562) T: 70.17% (4311)	Percentage and raw count of non-gap S: 99.87% (6136) other: 0.13% (8) L: 99.09% (6088) other: 0.91% (56) F: 48.76% (2996) Y: 46.88% (2880) other: 4.36% (268) N: 99.71% (6126) other: 0.29% (18) T: 90.89% (5584) A: 6.46% (397) other: 2.65% (163) V: 76.11% (4676) I: 20.51% (1260) other: 0.33% (208) A: 90.53% (5562) V: 8.61% (529) other: 0.86% (53) T: 70.17% (4311) V: 29.30% (1800) other: 0.54% (33) Other: 0.54% (33)	Percentage and raw count of non-gap Non-gap/total (percentage) S: 99.87% (6136) other: 0.13% (8) 6144/6144 (100.00%) L: 99.09% (6088) other: 0.91% (56) 6144/6144 (100.00%) F: 48.76% (2996) Y: 46.88% (2880) other: 4.36% (268) 6144/6144 (100.00%) F: 48.76% (2996) Y: 46.88% (2880) other: 4.36% (268) 6144/6144 (100.00%) N: 99.71% (6126) other: 0.29% (18) 6144/6144 (100.00%) T: 90.89% (5584) A: 6.46% (397) other: 3.39% (208) 6144/6144 (100.00%) V: 76.11% (4676) I: 20.51% (1260) other: 3.39% (208) 6144/6144 (100.00%) A: 90.53% (5562) V: 8.61% (529) other: 0.86% (53) 6144/6144 (100.00%) T: 70.17% (4311) V: 29.30% (1800) other: 0.54% (33) 6144/6144 (100.00%)

HIV QuickAlign or AnalyzeAlign tools show that the third site, Y, is often F

Is this due to some clades of virus having Y, others F, or is it F/Y within each clade?





AnalyzeAlign

Input options

Alignment: imported from QuickAlign (4661 amino acid sequence(s)) Major subtypes only Group the sequences: separately report results for subsets grouped by user's grouping choice Logo stack width: 22 Stacks per line: 25 Units: probability Show x-axis: yes Show y-axis: yes Color scheme: hydrophobicity Draw stacks with largest letters on top: yes Remove symbols from logo: show all Mark potential N-linked glycosylation sites: no Delete gaps and shift alignment to C-terminus: no Cut-off for calculating frequency by position: 95% Master sequence for finding variants: SLYNSVATL

Warning: Your sequences had to be padded - please make sure all sequences are of the same length.

Download all results: ZIP

Groups

$\underline{B} \ \underline{A1} \ \underline{A2} \ \underline{C} \ \underline{D} \ \underline{F1} \ \underline{F2} \ \underline{G} \ \underline{01_AE} \ \underline{02_AG}$

Group B

Download: PNG

Frequency by position

See	full raw counts			cutoff: 95
		Percentage and raw count of non-gap	Non-gap/total (percentage)	Gap/total (percentage)
1	S: 99.84% (1874)	other: 0.16% (3)	1877/1877 (100.00%)	0/1877 (0.00%)
2	L: 98.03% (1840)	other: 1.97% (37)	1877/1877 (100.00%)	0/1877 (0.00%)
3	Y: 59.51% (1117)	F: 37.51% (704) other: 2.98% (56)	1877/1877 (100.00%)	0/1877 (0.00%)
4	N: 99.57% (1869)	other: 0.43% (8)	1877/1877 (100.00%)	0/1877 (0.00%)
5	T: 89.50% (1680)	A: 8.26% (155) other: 2.24% (42)	1877/1877 (100.00%)	0/1877 (0.00%)
6	V: 74.43% (1397)	I: 24.29% (456) other: 1.28% (24)	1877/1877 (100.00%)	0/1877 (0.00%)
7	A: 98.40% (1847)	other: 1.60% (30)	1877/1877 (100.00%)	0/1877 (0.00%)
8	T: 54.77% (1028)	V: 44.91% (843) other: 0.32% (6)	1877/1877 (100.00%)	0/1877 (0.00%)
9	L: 99.09% (1860)	other: 0.91% (17)	1877/1877 (100.00%)	0/1877 (0.00%)

Go to top


Viewing each subtype separately, we see that the Y vs F at the third site is common in all clades or subtypes of HIV-1





B.CN.2009.2832.10900872 Gag B.CN.2009.2842.JQ900881_Gag B.CN.2009.2845.10900884 Gad B.CN.2009.2848.10900885 Ga B.CN.2009.2916-gag.KT191801 Gad B.CN.2009.2925-gag.KT191805 Gag B.CN.2009.2926-gag.KT191806 Gad B.CN.2009.2936-gag.KT191809 Gag B.CN.2009.2952-gag.KT191810 Gad B.CN.2009.2960-gag.KT191811 B.CN.2009.2963-gag.KT191812_Gag B.CN.2009.2977-gag.KT191813 B.CN.2009.2981-gag.KT19181 B.CN.2009.3034-gag.KT191823 B.CN.2009.3043-gag.KT191824 Gag B.CN.2009.3102-gag.KT191825_Gag B.CN.2009.3111-gag.KT191826_Gag B.CN.2009.3132-gag.KT191827_Gag B.CN.2009.3148-gag.KT191828_Gag B.CN.2009.3152-gag.KT191829_Gag B.CN.2009.3170-gag.KT191830_Gag B.CN.2009.3190-gag.KT191832_Gag B.CN.2009.3196-gag.KT191833 B.CN.2009.3197-gag.KT191834 B.CN.2009.3200-gag.KT191837 B.CN.2009.3206-gag.KT191838 B.CN.2009.3207-gag.KT19183 B.CN.2009.3422x-gag.KT1918 B.CN.2009.3465-gag.KT191843 B.CN.2009.3467-gag.KT191844_Gag B.CN.2009.3488-gag.KT191845_Gag B.CN.2009.3513-gag.KT191847 Gag B.CN.2009.DEMB09CN002.KC596066 Gag 3.CN.2009.YN09P0014.IE932494 Gag 3.CN.2009.ZHP-10-gag.KT191850 Ga 3.CN.2009.ZHP-11-gag B.CN.2009.ZHP-13-gad B.CN.2009.ZHP-14-gag B.CN.2009.ZHP-16-gag.KT B.CN.2009.ZHP-18-gag B.CN.2009.ZHP-23-gag.KT191864 Gad B.CN.2009.ZHP-25-gag.KT191866 Gag B.CN.2009.ZHP-26-gag.KT191867 Gag B.CN.2009.ZHP-29-gag.KT191870_Gag B.CN.2009.ZHP-30-gag.KT191872_Gag B.CN.2009.ZHP-31-gag.KT191873_Gag B.CN.2009.ZHP-32-gag.KT191874_Gag







Exploring that region of the HIV-1 sequence alignment, we see it is a TAC = Y vs TTC = F transversion in the genome. Nearby, ACC = T vs GTC = V is not co-varying with the Y vs F.

SEEL





No. of mutations



	1529	24.89	0
F	1383	22.51	1
V-	396	6.45	1
FV-	389	6.33	2
FI	330	5.37	2
I-V-	219	3.56	2
I	181	2.95	1
FI-V-	178	2.9	3
FV	108	1.76	2
V	107	1.74	1
F-AV-	100	1.63	3
FIV	85	1.38	3
н	81	1.32	1
AV-	56	0.91	2
F-A	56	0.91	2

Overall, 24.89% of HIV-1 have SLYNTVATL

22.51% are SLFNTVATL 6.45% are SLYNTVAVL 6.33% are SLFNTVAVL

Years ago, we noted that many sites "toggled" back and forth between two amino acids, and that the top few most common forms of each epitope thus made up the majority.

This was the birth of our "Mosaic Vaccine Design" which has been proven useful not only for HIV vaccines but also for vaccines against several other viruses.



The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope. Kan-Mitchell J, Bisikirska B, Wong-Staal F, Schaubert KL, Bajcz M, Bereta M. J Immunol. 2004 May 1;172(9):5249-61. doi: 10.4049/jimmunol.172.9.5249. PMID: 15100263 Free article.

The CTL response to the HLA-A*0201-restricted, HIV-1 **p17 Gag**(77-85) epitope (**SLYNTVATL**; SL9) has been extensively studied in patients. ...In contrast to published reports for influenza and melanoma peptides and the HIV **gag** IV9 epitope studied here in p ...

Characterization of cross-reactive CD8+ T-cell recognition of HLA-A2restricted HIV-**Gag (SLYNTVATL)** and HCV-NS5b (ALYDVVSKL) epitopes in individuals infected with **human immunodeficiency** and hepatitis C viruses. Vali B, Tohn R, Cohen MJ, Sakhdari A, Sheth PM, Yue FY, Wong D, Kovacs C, Kaul R, Ostrowski MA. J Virol. 2011 Jan;85(1):254-63. doi: 10.1128/JVI.01743-10. Epub 2010 Oct 27.

PMID: 20980521 Free PMC article.

The immunologic mechanisms underlying the faster progression of hepatitis C **virus** (HCV) disease in the presence of **human immunodeficiency virus** (HIV) coinfection are not clearly understood. ...Our search for amino acid sequence homology between the HCV ...

Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART.

Zidovec Lepej S, Kosor E, Gagro A, Vince A, Remenar A, Poljak M. Coll Antropol. 2006 Dec;30 Suppl 2:33-8.

PMID: 17508471

Gag SLYNTVATL-specific CD8+ T-cells were detectable in 18 of 26 treated patients (median 5.2 years of HAART) and in 10 of 14 untreated patients. Median percentage of **Gag SLYNTVATL**-specific CD8+ T-cells in treated patients was 0.10 (range 0.00-0.70%).

Intrapatient escape in the A*0201-restricted epitope **SLYNTVATL** drives evolution of **human immunodeficiency virus** type 1 at the population level. Edwards CT, Pfafferott KJ, Goulder PJ, Phillips RE, Holmes EC. J Virol. 2005 Jul;79(14):9363-6. doi: 10.1128/JVI.79.14.9363-9366.2005. PMID: 15994836 Free PMC article. The hypothesis that the intrapatient emergence of cytotoxic T-lymphocyte escape variants

contributes to the evolution of **human immunodeficiency virus** type 1 at the population (interpatient) level was tested using the HLA-A*0201-restricted **gag p17** ... A PubMed search for "SLYNTVATL" hits 55 papers.

HIV Immunology Database at LANL has 301 records for SLYNTVATL and 14 for SLFNTVATL

How do we explore the evolution of this epitope in the HIV Sequences Database?



B.FR. 1983. HXB2-LAI-IIIB-BRU.K03455 C.ZM.2006.ZM1044M_25Mar2006_SC_10.A_N.MT194167 C.ZM.2011.ZM1044M_16Aug2011_1A_23_N.MT194138 C.ZM.2006.ZM1044M_25Mar2006_SC_10.B_N.MT194168 C.ZM.2006.ZM1044M_25Mar2006_SC_11_N.MT194169 C.ZM.2006.ZM1044M_25Mar2006_SC_1_N.MT194170 C.ZM.2006.ZM1044M 25Mar2006 SC 3 N.MT194171 C.ZM.2006.ZM1044M 25Mar2006 SC 4 N.MT194172 C.ZM.2006.ZM1044M_25Mar2006_SC_5_N.MT194173 C.ZM.2006.ZM1044M_25Mar2006_SC_6_N.MT194174 C.ZM.2006.ZM1044M_25Mar2006_SC_7_N.MT194175 C.ZM.2006.ZM1044M_25Mar2006_SC_8_N.MT194176 C.ZM.2006.ZM1044M_25Mar2006_SC_9_N.MT194177 C.ZM.2006.ZM1044M_25Mar2006_TF_NFLG.MT194178 C.ZM.2008.ZM1094F_04Jul2008_SC_10_N.MT194314 C.ZM.2008.ZM1094F_04Jul2008_SC_11_N.MT194315 C.ZM.2008.ZM1094F_04Jul2008_SC_12.A_N.MT194316 C.ZM.2008.ZM1094F 04lul2008 SC 12.B N.MT194317 C.ZM.2008.ZM1094F 04Jul2008 SC 1 N.MT194318 C.ZM.2008.ZM1094F_04Jul2008_SC_2_N.MT194319 C.ZM.2008.ZM1094F_04Jul2008_SC_3_N.MT194320 C.ZM.2008.ZM1094F_04Jul2008_SC_4_N.MT194321 C.ZM.2008.ZM1094F_04lul2008_SC_5_N.MT194322 C.ZM.2008.ZM1094F 04Jul2008 SC 6 N.MT194323 C.ZM.2008.ZM1094F_04Jul2008_SC_7_N.MT194324 C.ZM.2008.ZM1094F_04Jul2008_SC_8_N.MT194325 C.ZM.2008.ZM1094F_04Jul2008_SC_9_N.MT194326 C.ZM.2008.ZM1094F 04lul2008 TF NFLG.MT194327 C.ZM.2011.ZM1094F_13Aug2011_1A_1_N.MT194338 C.ZM.2011.ZM1094F_13Aug2011_1A_2_N.MT194343 C.ZM.2011.ZM1094F_13Aug2011_1A_3_N.MT194344 C.ZM.2012.ZM1123M_10Jan2012_1A_1_N.MT194468 C.ZM.2012.ZM1123M 10Jan2012 1A 2 N.HY.MT194478 C.ZM.2012.ZM1123M_10Jan2012_1A_3_N.MT194481 C.ZM.2012.ZM1123M_10Jan2012_1A_4_N.HY.MT194482 C.ZM.2012.ZM1123M_10Jan2012_1A_5_N.MT194483 C.ZM.2012.ZM1123M_10Jan2012_1A_6_N.MT194484 C.ZM.2012.ZM1123M 10lan2012 1A 7 N.MT194485 C.ZM.2008.ZM1123M_12Apr2008_SC_1_N.MT194488 C.ZM.2008.ZM1123M_12Apr2008_SC_2_N.MT194489 C.ZM.2008.ZM1123M_12Apr2008_SC_3_N.MT194490 C.ZM.2008.ZM1123M_12Apr2008_SC_4_N.MT194491 C.ZM.2008.ZM1123M 12Apr2008 SC 5 N.MT194492 C.ZM.2008.ZM1123M_12Apr2008_SC_6_N.MT194493 C.ZM.2008.ZM1123M_12Apr2008_SC_7_N.MT194494 C.ZM.2008.ZM1123M_12Apr2008_SC_8_N.MT194495 C.ZM.2008.ZM1123M_12Apr2008_TF_NFLG.MT194496 C.ZM.2008.ZM1123M_15May2008_SC_10_N.MT194497 C.ZM.2008.ZM1123M 15May2008 SC 9 N.MT194498 C.ZM.2006.ZM1124F_18May2006_SC_10_N.MT194600 C.ZM.2006.ZM1124F_18May2006_SC_1_N.MT194601 C.ZM.2006.ZM1124F_18May2006_SC_2_N.MT194602 C.ZM.2006.ZM1124F 18May2006 SC 3 N.MT194603 C.ZM.2006.ZM1124F 18May2006 SC 4 N.MT194604 C.ZM.2006.ZM1124F_18May2006_SC_5_N.MT194605 C.ZM.2006.ZM1124F_18May2006_SC_6_N.MT194606 C.ZM.2006.ZM1124F_18May2006_SC_7_N.MT194607 C.ZM.2006.ZM1124F_18May2006_SC_8_N.MT194608 C.ZM.2006.ZM1124F_18May2006_SC_9_N.MT194609 C.ZM.2006.ZM1124F_18May2006_TF_NFLG.MT194610 C.ZM.2006.ZM1165M_16Mar2006_SC_10_N.MT194738 C.ZM.2006.ZM1165M_16Mar2006_SC_11_N.MT194739 C.ZM.2006.ZM1165M 16Mar2006 SC 12 N.MT194740 C.ZM.2006.ZM1165M 16Mar2006 SC 1 N.MT194741 C.ZM.2006.ZM1165M 16Mar2006 SC 2 N.MT194742 C.ZM.2006.ZM1165M_16Mar2006_SC_3_N.MT194743 C.ZM.2006.ZM1165M 16Mar2006 SC 4 N.MT194744 C.ZM.2006.ZM1165M_16Mar2006_SC_5_N.MT194745 C.ZM.2006.ZM1165M 16Mar2006 SC 6 N.MT194746 C.ZM.2006.ZM1165M_16Mar2006_SC_7_N.MT194747 C.ZM.2006.ZM1165M_16Mar2006_SC_8_N.MT194748 C.ZM.2006.ZM1165M 16Mar2006 TF NFLG.MT194749 C.ZM.2011.ZM1658F_01Nov2011_1A_1_N.MT194782 C.ZM.2011.ZM1658F 01Nov2011 1A 2 N.MT194792 C.ZM.2006.ZM1658F_08Jun2006_Pop_A_TF_NFLG.MT194854 C.ZM.2006.ZM1658F_08Jun2006_Pop_B_TF_NFLG.MT194855 C.ZM.2006.ZM1658F 08lun2006 SC 10 N.MT194856 C.ZM.2006.ZM1658F_08Jun2006_SC_11_N.MT194857 C.ZM.2006.ZM1658F 08Jun2006 SC 12 N.MT194858 C.ZM.2006.ZM1658F_08Jun2006_SC_13_N.MT194859 C.ZM.2006.ZM1658F_08Jun2006_SC_14_N.MT194860 C.ZM.2006.ZM1658F_08Jun2006_SC_15_N.MT194861 C.ZM.2006.ZM1658F_08Jun2006_SC_16_N.MT194862 C.ZM.2006.ZM1658F 08lun2006 SC 17 N.MT194863 C.ZM.2006.ZM1658F 08Jun2006 SC 1 N.MT194864 C.ZM.2006.ZM1658F_08Jun2006_SC_3_N.MT194865 C.ZM.2006.ZM1658F 08lun2006 SC 4 N.MT194866 C.ZM.2006.ZM1658F_08Jun2006_SC_5_N.MT194867 C.ZM.2006.ZM1658F_08Jun2006_SC_6_N.MT194868 C.ZM.2006.ZM1658F 08lun2006 SC 7 N.MT194869 C.ZM.2006.ZM1658F_08Jun2006_SC_8_N.MT194870 C.ZM.2006.ZM1658F_08Jun2006_SC_9_N.MT194871

HIV Sequence Database Intrapatient Sets search for Gag-p17 region from early infection.

Does one form of the epitope (SLYNTVATL vs SLFNTVATL) tend to dominate early infections, as the "transmitted/founder" virus?

Apparently not.

In this study only one patient showed heterogeneity of the epitope early in infection, and not at either of the two "toggle sites".



	100		·		9	10
B.KR.1992.92YW56.MK577480			FN	TVA	TLYCV	V
B.KR.1992.92YWS6-16533.MK548754	: 1	(SL	F N	TVA	TLYCV	V
B.KR.1992.92YWS6-16666.MK548755	: F	S L	F N	TVA	TLCC	v
B.KR.1991.91DonorO.KF561442	, F	S L	FN	TVA	TLYCV	v
B.KR.1991.91DOnorO-16463-Plasma.MK548701	, F	S L	FN	TVA	TLYCY	v
B.KR.1991.91DonorO-16462-Plasma.MK548700					TLYC	
B.KR.1993.93DonorP.MK577478					TLYCY	
B.KR.1993.93DonorP-16468-Plasma.MK548702					TLYC	
B.KR.1993.93DonorP-16469-Plasma.MK548703					TLYCV	
B.KR.1992.HP-7-96LSM10-3474.KJ140252	I	SL	F N	TVA	TLYCV	7
B.KR.1996.96LSM10-3474.JN613671	, R	S L	F N	TVA	TLYCV	V
B.KR.1993.93LSM4-16457-HP-7.MK548716	: K	SL	FN	TVA	TLYCV	V
B.KR.1996.HP-7-96LSM10.MT679553	, R	S L	FN	TVA	TLYCV	v
B.KR.1996.96LSM10-3475.JN613672	K	SL	FN	SVA	TLYCY	v
B.KR.2019.HP-7-19LSM8-Aug-2019A.MT559052					TLYC	
B.KR.2019.HP-7-19LSM8-Aug-2019B.MT559053					TLYCY	
B.KR.2003.HP-6-03JHJ2.MT679552					TLYC	
					TLYC	
B.KR.2019.HP-6-19JHJ7-Jul-2019.MT559051						
B.KR.2003.03YGS3.JQ316135					TLYCV	
B.KR.2005.05YGS8-2623.EF370360					TLYCV	
B.KR.2005.05YGS8-2622.EF370361	. F	S L	F N	TVA	TLYCV	1
B.KR.2004.04YGS8-2626.EF370359	, K	S L	F N	TVA	TLYCV	V
B.KR.2010.07YGS10-3903-3901-3896.JX174436	, K	S L	F N	TVA	TLYCV	V
B.KR.1997.97LSM2-5544s1.JN613598	, R	S L	FN	LVA	TLYC	V
B.KR.2000.00KMH12-2732.EF370273					TLYC	
B.KR.2001.01KMH11-2740.EF370274					TLYCY	
B.KR.2003.03KMH2-3144.EU047672					TLYC	
B.KR.2005.05KMH9-2733.EF370281					TLYC	
B.KR.2005.05KMH3-12177.MK548831					TLYC	
B.KR.2006.06KMH2-3096.EU047670					TLYCV	
B.KR.2003.03KMH2-3097.EU047671	. F	S L	F N	TVA	TLYCV	V
B.KR.2004.04KMH5.DQ295193	. K	(S L	F N	TVA	TLYCV	V
B.KR.1993.93KJS7-2433.EF370183	. F	S L	F N	TVA	TLYCV	V
B.KR.2001.01KJS7-2671s.EF370193	. F	SL	FN	TIA	TLYC	v
B.KR.2002.02KJS1-12188.MK548741					TLYCY	
B.KR.2004.04KJS8.JQ316130					TLYCY	
B.KR.2008.08KJS7-12189-1.MK548742					TLYCY	
B.KR.1999.99KJS6-2886.EF370189					TLYC	
-			And a local division of the local division o			
B.KR.1999.99KJS6-2887.EF370190					TLYC	
B.KR.1991.91KJS12-16513.MK548740					TLYCV	
B.KR.1991.91KJS12-16479.MK548739					TLYCV	
B.KR.1992.92KJS11.MN043596	, R	(S L	F N	TVA	TLYCV	7
B.KR.1991.91KDG8-2715.EF370312	, F	(S L	FN	TVA	TLYCV	V
B.KR.1994.94LSH8-2894.EF370209	. F	S L	FN	TVA	TLYCV	v
B.KR.1992.92LSH6-16509.MK548756	, F	S L	FN	TVA	TLYCV	v
B.KR.1993.93LSH5.MN043583					TLYC	
B.KR.1993.93LSH6-1740.EF370206					TLYCY	
B.KR.1994.94LSH5-2878.EF370208					TLYC	
B.KR.1994.94LSH5-3160.EU047642					TLYC	
B.KR.1994.94LSH8-2895.EF370210					TLYC	
B.KR.1992.92CYK6.MN043598					TLYC	
B.KR.1992.92CYK6-16534.MK548793					TLYCV	
B.KR.1992.92LSY12.MN043589	, R	SL	F N	TVA	TLYCV	V
B.KR.1992.92LSY12-16475.MK548738	, F	SL	F N	TVA	TLYCV	V
B.KR.1993.93KDG4-16488.MK548759	. F	(SL	FN	TVA	TLYCV	V
B.KR.1993.93KDG4-16670s1.MK548877	, K	S L	FN	TVA	TLYC	V
B.KR.1993.93KDG4-16646.MK548760	100				TLYC	
B.KR.2002.02KJin12-2877.EF370222					TLYC	
B.KR.1991.91LYS8-4501.JN613632					TLYC	
B.KR.1992.HP-1-92LYS9-4500.KJ140245					TLYC	
					TLYC	
B.KR.1992.HP-1-92LYS9-4501.KJ140246			-			
B.KR.1992.9285Jn6-16525.MK548799					TLYC	
B.KR.1992.92BSJn6-16660.MK548800			The second se		TLYC	
B.KR.2002.02OSG1-3332.EU047640					TLYCY	
B.KR.1999.990SG2-3313.EU047636					TLYCV	
B.KR.2002.02OSG1.JQ429433					TLYCV	
B.KR.2001.01OSG2-3316.EU047637	, R	S L	F N	TVA	TLYCV	V
B.KR.1999.99OSK2-2449.EF370306	, K	S L	FN	TVA	TLYC	V
B.KR.2003.03KGJ10-4876.JN613650	, K	SL	FN	TIA	TLYC	v
B.KR.2019.HP-4-19KGJ7-Jul-2019.MT559050					TLYC	
B.KR.1993.93KGJ10-16505-HP-4.MK548710					TLYC	
B.KR.2009.09KGJ12-6979.JN613654					TLYC	
B.KR.2019.19KGI7-HP-4-17314.MW523059					TLYC	
		<u> </u>	I	- VA		_

HIV Sequence Database Korean hemophiliac cohort sampled over many years. All infected from two donors.

Does the SLYNTVATL epitope show signs of escape variation?

Apparently not.

In this study the infecting virus had SLFNTVATL and there was little change observed between 1991 donor up to 2019 recent samples.



Ab.LV.2001.01LV_N0731.AY290880
A6.LV.2001.01LV_N0732.AY290881
A6.LV.2001.01LV_N0733.AY290882
A6.LV.2001.01LV_N0735.AY290884
A6.LV.2001.01LV_N0740.AY290887
A6.LV.2001.01LV_N0747.AY290890
A6.LV.2001.01LV_N0751.AY290894
A6.LV.2001.01LV_N0762.AY290905
A6.LV.2001.01LV_N0766.AY290908
A6.LV.2001.01LV_N0767.AY290909
A6.LV.2001.01LV_N0769.AY290911
A6.LV.2001.01LV_N0770.AY290912
A6.LV.2001.01LV_N0746.AY290913
A6.LV.2001.01LV_N0773.AY290915
A6.LV.2001.01LV_N0791.AY290919 A6.LV.2001.01LV_N0792.AY290920
A6.LV.2001.01LV_N0794.AY290922
A6.LV.2001.01LV_N0796.AY290923
A6.LV.2001.01LV_N0783.AY290924
A6.LV.2001.01LV N0798.AY290925
A6.LV.2001.01LV_N0801.AY290928
A6.LV.2001.01LV_N0802.AY290929
A6.LV.2001.01LV_N0806.AY290931
A6.LV.2001.01LV_N0759.AY290934
A6.LV.2001.01LV_N0823.AY290942
A6.LV.2001.01LV_N0824.AY290943
A6.LV.2001.01LV_N0825.AY290944
A6.LV.2001.01LV_R135.AY290948
A6.LV.2001.01LV_V612.AY290949
A6.LV.2001.01LV_Z325.AY290950
A6.LV.2001.01LV_H552.AY290953
A6.LV.2001.01LV_B251.AY290954
A6.LV.2001.01LV_\$152.AY290961
A6.LV.2000.00LV_N0128.AY290962
A6.RU.2003.03RU20_06_13.AY500393
A6.RUNo2333.EF119574
A6.RUNo3107.EF119575
A6.RUNo2025.EF119576
A6.RUNo2662.EF119578
A6.RUNo2259.EF119579
A6.RUNo2085.EF119580 A6.RUNo2670.EF119582
A6.RUNo2358.EF119583
A6.RUNo2159.EF119585
A6.RUNo2679.EF119586
A6.RUNo3109.EF119587
A6.RUNo2655.EF119588
A6.RUpatient_2353.EF121244
A6.RUpatient_2249.EF121247
A6.RUpatient_3183.EF121248
A6.RUpatient_3176.EF121249
A6.RUpatient_3141.EF121250
A6.RUpatient_2162.EF121251
A6.RUpatient_2354.EF121252
A6.RUpatient_2086.EF121253
10 BU

	,	,				80		-			1		
1	Г	K	S	ь	Y	N	т	v	A	т	Г	¥	C
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	т	v	A	т	L	Y	С
	L	K	s	L	Y	N	т	v	A	т	L	Y	с
	L	K	s	L	Y	N	т	V	A	т	L	Y	C
	L	K	s	L	Y	N	т	V	A	т	L	Y	C
	L	ĸ	s	L	Y	N	т	v	A	т	L	Y	C
	L	K	S	L	Y	N	T	v	A	T	L	Y	C
	L	K	S	L	Y	N	v	v	A	T	L	Y	c
	L	K	S	L	Y	N	Т	v	A	T	L	Y	c
	L	K	S	L	Y	N	т	v	A	Т	L	Y	c
								v					
	L	K	S	L	Y	N	Т		A	Т	L	Y v	C
	L	K	S	L	Y	N	T	V	A	T	L	Y	C
	L	K	S	L	Y	N	T	V	A	Т	L	Y	C
	L	K	S	L	Y	N	T	V	A	Т	L	Y	C
	L	K	S	L	Y	N	Т	V	A	Т	L	Y	C
	L	K	S	L	F	N	Т	V	A	Т	L	Y	C
	L	K	s	L	Y	N	Т	V	A	Т	L	Y	С
	L	K	s	L	Y	N	Т	V	A	Т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	ĸ	s	L	Y	N	т	v	A	т	L	Y	С
	L	ĸ	s	L	Y	N	т	v	A	т	L	Y	С
	L	K	S	L	Y	N	т	V	A	т	L	Y	C
	L	K	S	L	Y	N	T	v	A	Т	L	Y	C
	L	K	S	L	Y	N	A	v	A	T	L	Y	c
	L	K	S	L	Y	N	Т	v	A	T	L	Y	c
	L	K	S	L	Y	N	T	v	A	т	L	Y	c
	L	K	S	L	Y	N	A	V	A	Т	L	Y	c
								V		Т			
	L	K	S	L	Y	N	T	V	A		L	Y	C
	L	K	S	L	Y	N	T	V	A	Т	L	Y	C
	L	R	S	L	Y	N	Т	V	A	Т	L	Y	C
	L	K	S	L	F	N	Т	V	A	T	L	Y	C
	L	K	S	L	F	N	Т	V	A	V	L	Y	С
	I	K	S	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	Т	V	A	Т	L	Y	С
	L	K	s	L	Y	N	Т	V	A	Т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	С
	L	ĸ	s	L	Y	N	т	V	A	т	L	Y	С
	L	K	s	L	Y	N	т	V	A	т	L	Y	с
	L	ĸ	s	L	Y	N	т	v	A	т		Y	с
	L	K	S	L	Y	N	т	V	A	т	L		C
	v	K	S	L	Y	N	T	v	A	T	L	Y	c
0	L	K	S	L	F	N	т	v	A	Т	L		c
	L	K	S	L	Y	N	Т	v	A	Т	L	Y	c
							Т			Т		r Y	c
	L	K	S	L	Y Y	N N	т	v v	A A	т Т	L L		
		7.5				ALC: N	100		10	111	100	× 1	
	L L	K K	S S	L L	H	N	т	v	A	T		Y	C C

Subsubtype A6 has spread through the former Soviet Union Region, primarily via IVDU, since the mid-1990s.

Not much conversion to SLFNTVATL has taken place.



Searching Immunology Database for MHC/HLA A*02 and proven diminished response in a Gag epitope, identifies SLFNTIATL as an escape variant.

Displaying record number 54556

HXB2 Location	Gag (77-85) Gag Epitope Map View variants at this location
Epitope	SLYNTVATL Epitope Alignment
Variants	SLFNTiATL diminished response; escape documented in this paper
Epitope Name	SL9
Species (MHC/HLA)	human(A*02)
Variant Detai	
Variant ID.	634
Epitope Seq.	SLYNTVATL
Variant Seq.	SLfNTiATL
Mutations	Y/F V/I
Epitope Location	Y3F V6I
HXB2 Location	Y79F V821
Mutation	DR: diminished response
Туре	E: escape documented in this paper
Method	CD8 T-cell Elispot - IFNy
Note	Variant detected by week 63. Lower magnitude responses than wt and V/I mutant. Positive selection. Seen with upstream changes E62G/V/A, where the 62A mutation persisted and is suggested to reduce fitness cost of the Y/F escape mutation.

References

Karlsson2007 Annika C. Karlsson, Astrid K. N. Iversen, Joan M. Chapman, Tulio de Oliviera, Gerald Spotts, Andrew J. McMichael, Miles P. Davenport, Frederick M. Hecht, and Douglas F. Nixon. Sequential Broadening of CTL Responses in Early HIV-1 Infection Is Associated with Viral Escape. *PLoS ONE*, 2:e225, 2007. PubMed ID: <u>17311088</u>. <u>Show all entries for this paper</u>.

Karlsson2007 paper has link to sequence data EF396480–EF396891








Figure 6. Phylogenetic tree illustrating viral evolution of the HIV-p17 gag region (HXB2 coordinates 790–1431) in subject OP428 under selective pressure. Positively selected amino acid sites within the HLA-A2 ((SL9, ⁷⁷SLYNTIATL⁸⁵ (patient consensus)), HLA-A1 (GY9, ⁷¹GSEELRSLY⁷⁹), and HLA-B8 (EL9, ⁹³EVKDTKEAL¹⁰¹) restricted epitopes. Amino acids corresponding to the consensus B sequence are shown in blue, while the Y79F mutation within SL9 and GY9 is given in red, and the E93D and V94I mutations within EL9 are shown in green on the tree. The variation found at the positively selected amino acid position 62, where a potential compensatory mutation (E62A) seems to occur prior to, and associated with, the Y79F substitution are as follows: variation at position 62: E, blue, G, orange, V purple and A red. Amino acid numbering corresponds to HXB2 Gag. Scale bars signify substitutions/site. w: corresponds to estimated week from infection (e.g. a clone named 428_w15 was obtained from a plasma sample drawn at week 15). doi:10.1371/journal.pone.0000225.g006

B.US.2002.B_US_02_OP599_089_20281.EF396637 B.US.2004.B US 04 OP599 159 02396.EF396639 B.US.2004.B_US_04_OP599_159_02396.EF396640 B.US.2004.B_US_04_OP599_159_02396.EF396641 B.US.2004.B_US_04_OP599_159_02396.EF396642 B.US.2004.B_US_04_OP599_159_02396.EF396643 B.US.2004.B_US_04_OP599_159_02396.EF396644 B.US.2004.B US 04 OP599 159 02396.EF396645 B.US.2004.B US 04 OP599 159 02396.EF396646 B.US.2004.B_US_04_OP599_159_02396.EF396647 B.US.2004.B_US_04_OP599_159_02396.EF396648 B.US.2004.B_US_04_OP599_159_02396.EF396649 B.US.2004.B_US_04_OP599_159_02396.EF396650 B.US.2004.B US 04 OP599 159 02396.EF396651 B.US.2004.B US 04 OP599 159 02396.EF396652 B.US.2004.B_US_04_OP599_159_02396.EF396653 R US 2004 R US 04 OP599 159 02396 FE396654 B.US.1999.B US 99 OP428 015 14228.EF396811 B.US.1999.B US 99 OP428 015 14228.EF396812 B.US.1999.B US 99 OP428 015 14228.EF396813 B.US.1999.B US 99 OP428 015 14228.EF396814 B.US.1999.B_US_99_OP428_015_14228.EF396815 B.US.1999.B_US_99_OP428_015_14228.EF396816 B.US.1999.B_US_99_OP428_015_14228.EF396817 B.US.1999.B_US_99_OP428_015_14228.EF396818 B.US.1999.B US 99 OP428 015 14228.EF396819 B.US.1999.B US 99 OP428 015 14228.EF396820 B.US.1999.B_US_99_OP428_015_14228.EF396821 B.US.1999.B US 99 OP428 015 14228.EF396822 B.US.1999.B US 99 OP428 015 14228.EF396823 B.US.1999.B_US_99_OP428_015_14228.EF396824 B.US.1999.B US 99 OP428 015 14228.EF396825 B.US.1999.B US 99 OP428 015 14228.EF396826 B.US.2000.B US 00 OP428 039 05867.EF396827 B.US.2000.B US 00 OP428 039 05867.EF396828 B.US.2000.B US 00 OP428 039 05867.EF396829 B.US.2000.B US 00 OP428 039 05867.EF396830 B.US.2000.B.US.00. OP428.039.05867.EE396831 B.US.2000.B US 00 OP428 039 05867.EF396832 B.US.2000.B US 00 OP428 039 05867.EF396833 B.US.2000.B US 00 OP428 039 05867.EF396834 B.US.2000.B US 00 OP428 039 05867.EF396835 B.US.2000.B US 00 OP428 039 05867.EF396836 B.US.2000.B.US.00.0P428.039.05867.EE396837 B.US.2000.B US 00 OP428 039 05867.EF396838 B.US.2000.B US 00 OP428 039 05867.EF396839 B.US.2000.B US 00 OP428 039 05867.EF396840 B.US.2000.B US 00 OP428 063 13074.EF396841 B.US.2000.B US 00 OP428 063 13074.EE396842 B.US.2000.B US 00 OP428 063 13074.EF396843 B.US.2000.B US 00 OP428 063 13074.EF396844 B.US.2000.B US 00 OP428 063 13074.EF396845 B.US.2000.B US 00 OP428 063 13074.EF396846 B.US.2000.B US 00 OP428 063 13074.EF396847 B.US.2000.B US 00 OP428 063 13074.FF396848 B.US.2000.B US 00 OP428 063 13074.EF396849 B US 2000 B US 00 OP428 063 13074 FE396850 B.US.2000.B US 00 OP428 063 13074.EF396851 B.US.2000.B US 00 OP428 063 13074.EF396852 B.US.2001.B_US_01_OP428_088_06550.EF396853 B.US.2001.B US 01 OP428 088 06550.EF396854 B.0. 2001.B_US_01_OP428_088_06550.EF396855 US_01_OP428_088_06550.EF396856 B US 200 B.US.2001.B US 21 OP428 088 06550.EF396857 B.US.2001.B US 01 OF 128 088 06550.EF396858 B.US.2001.B_US_01_OP428_068_06550.EF396859 B.US.2001.B_US_01_OP428_088_06550_EF396860 B.US.2001.B US 01 OP428 088 06550.EF326861 B US 2001 B US 01 OP428 088 06550 FE39686 B.US.2001.B US 01 OP428 088 06550.EF396863 B.US.2001.B US 01 OP428 088 06550.EF396864 B.US.2001.B US 01 OP428 088 06550.EF396865 B.US.2001.B US 01 OP428 088 06550.EF396866 B.US.2002.B_US_02_OP428_139_08823.EF396867 B US 2002 B US 02 OP428 139 08823 FF396868 B.US.2002.B US 02 OP428 139 08823.EF396869 B.US.2002.B US 02 OP428 139 08823.EF396870 B.US.2002.B_US_02_OP428_139_08823.EF396871 B.US.2002.B US 02 OP428 139 08823.EF396872 B.US.2002.B_US_02_OP428_139_08823.EF396873 B.US.2002.B US 02 OP428 139 08823.EF396874 B.US.2002.B US 02 OP428 139 08823.EF396875 B.US.2002.B_US_02_OP428_139_08823.EF396876 B.US.2002.B_US_02_OP428_139_08823.EF396877 B.US.2002.B US 02 OP428 156 17789.EF396878 B.US.2002.B US 02 OP428 156 17789.EF396879 B.US.2002.B US 02 OP428 156 17789.EF396880 B.US.2002.B US 02 OP428 156 17789.EF396881 B.US.2002.B US 02 OP428 156 17789.EF396882 B.US.2002.B_US_02_OP428_156_17789.EF396883 B.US.2002.B US 02 OP428 156 17789.EF396884 B.US.2002.B US 02 OP428 156 17789.EF396885 B.US.2002.B US 02 OP428 156 17789.EF396886 B.US.2002.B US 02 OP428 156 17789.EF396887 B.US.2002.B US 02 OP428 156 17789.EF396888 B.US.2002.B_US_02_OP428_156_17789.EF396889 B.US.2002.B US 02 OP428 156 17789.EF396890 B.US.2002.B_US_02_OP428_156_17789.EF396891

P EP 1092 HVP2-I AL-IIIP-PPIL K02455

OP599 OP428

IDV

BORATORY

LYCVHOGI


ATLYCVHQGIEV

TLYCVHQGIEV

ATLYCVHQGIEV

TIATLYCVHQGIEV

LY<mark>NTIATLYCVHQG</mark>I



B.US.2002.B_US_02_0P478_112_10340b.EF396528 B.US.2002.B_US_02_0P478_112_10340a.EF396527 selected amino acid position 62, where a potential compensatory mutation (E62A) seems to occur prior to, and associated with, the Y79F substitution are as follows: variation at position 62: E, blue, G, orange, V purple and A red. Amino acid numbering corresponds to HXB2 Gag. Scale bars signify substitutions/site. w: corresponds to estimated week from infection (e.g. a clone named 428_w15 was obtained from a plasma sample drawn at week 15). doi:10.1371/journal.pone.0000225.q006

Subsubtype A6 one per patient




Subtype B two patients OP428 is HLA A02

	AliView - SLY	NTVATL_Escape2007_Gag.FASTA		Search
R.U2.2005.R_02_05_05_0882_50581.51386633				
B.US.2002.B_US_02_OP599_089_20281.EF396634	С А G А А G А А C ТТАА	А Т С А ТТА <mark>ТТТ</mark> ААТА <mark>С</mark> ААТ	A G C A G T C A T C T A T T G T	G T A C A T C A A A G G
B.US.2002.B_US_02_OP599_089_20281.EF396635	С А G А А G А А C ТТАА	А Т С А ТТА ТАТААТА СААТ	A G C A G T C A T C T G T T G T	G T A C A T C A A A G A
B.US.2002.B_US_02_OP599_089_20281.EF396636	C A G A A G A A <mark>C T T</mark> A A	A T C A T T A T T T A A T A C A A T	A G C A G T C A T C T A T T G T	G T A C A T C A A A G G
B.US.2002.B_US_02_OP599_089_20281.EF396637	C A G A A G A G C T T A A	A T C A T T A T T T A A T A C A A T	A G C A G T C A T C T A T T G T	G T A C A T C A A A G G
B.US.2004.B_US_04_OP599_159_02396.EF396639	C A G A A G A A <mark>C T T</mark> A A	A T C A T T A <mark>C A</mark> T A A T A C A G T	A G C A G T C A T C T A T T G T	G T A C A T C A A A G G
B.US.2004.B_US_04_OP599_159_02396.EF396640	C A G A A G A A C T T A A	A T C A T T A T T T A A T A C A A T	A G C A G T C A T C T A T T G T	G T A C A T C A A A G G
B.US.2004.B_US_04_OP599_159_02396.EF396641 B.US.2004.B_US_04_OP599_159_02396.EF396642	C A G A A G A A C T T A A	ATCATTATTTAATACAAT	A G C A G T C A T C T A T T G T	GTACATCAAAGG
B.US.2004.B_US_04_0P599_159_02396.EF396643 B.US.2004.B_US_04_0P599_159_02396.EF396644	C A G A A G A A C T T A A		A G C A G T C A T C T A T T G T	G T A C A T C A A A G G
B.US.2004.B_US_04_OP599_159_02396.EF396645 B.US.2004.B_US_04_OP599_159_02396.EF396645 B.US.2004.B_US_04_OP599_159_02396.EF396646	C A G A A G A A C T T A A		A G C A G T C A T C T A T T G T	G T A C A T C A A A G G
B.US.2004.B_US_04_OP599_159_02396.EF396647	C A G A A G A A C T T A A	ATCATTATTTAATACAAT	A G C A G T C A T C T A T T G T	G T A C A T C A A A G G
B.US.2004.B_US_04_OP599_159_02396.EF396648 B.US.2004.B_US_04_OP599_159_02396.EF396649	C A G A A G A A C T T A A C A G A A G A A C T T A A	ATCATTATTAATACAAT ATCATTATTTAATACAAT ATCATTATTTAATACAAT	A G C A G T C A T C T A T T G T A G C A G T C A T C T A T T G T	G T A C A T C A A A G G G T A C A T C A A A G G
B.US.2004.B_US_04_OP599_159_02396.EF396650 B.US.2004.B_US_04_OP599_159_02396.EF396651	C A G A A G A A C T T A A C A G A A G A A C T T A A	АТСАТТАТТТААТАСААТ АТ <mark>САТТА</mark> ТТ <mark>ААТА</mark> СААТ АТ	A G C A G T C A T C T A T T G T A G C A G T C A T C T A T T G T	G T A C A T C A A A G G G T A C A T C A A A G G
B.US.2004.B_US_04_OP599_159_02396.EF396652 B.US.2004.B_US_04_OP599_159_02396.EF396653	C A G A A G A A C T T A A C A G A A G A A C T T A A	А Т С А Т Т А <mark>С А</mark> Т А А Т А С А С Т А Т <mark>С А Т Т А Т Т Т</mark> А А Т А <mark>С А А Т</mark> А Т С А Т Т А Т Т Т <mark>А А Т А С А А Т</mark>	'	G T A C A T C A A A G G G T A C A T C A A A G G
B.US.2004.B_US_04_OP599_159_02396.EF396654	C A G A A G A A C T T A A	А Т С А Т Т А Т Т Т А А Т А С А А Т	A G C A <mark>G T C</mark> A T C T A T T G T	G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396811	C G G A A G A A C T T A A	А Т С А Т Т G Т <mark>А Т</mark> А А Т А С А А Т	A G C A A <mark>C T C</mark> T C T A T T G T	G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396812	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396813	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396814	C G G A A <mark>G A A C T T</mark> A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396815	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A A <u>G G</u>
B.US.1999.B_US_99_OP428_015_14228.EF396816	C G G A A G A A C TT A G	А Т С А Т Т С Т А Т А А Т А <mark>С</mark> А А Т	'	G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396817	C G G A A G A A C TT A G	А Т С А Т Т С Т А Т А А Т А <mark>С</mark> А А Т		G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396818	<mark>С</mark> G G A A G A A <mark>C</mark> Т Т А G	А Т С А Т Т С Т А Т А А Т А <mark>С</mark> А А Т		G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396819	С G G A A G A A C Т Т А G	А Т С А Т Т С Т А Т А А Т А С А А Т		G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396820	<mark>C</mark> G G A A G A A <mark>C</mark> T T A G	A T C A T T G T A T A A T A C A A T		G T A <mark>C</mark> A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396821	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T		G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396822 B.US.1999.B_US_99_OP428_015_14228.EF396823	<mark>С</mark> G G A A G A A <mark>C Т Т</mark> А G С G G A A G A A C Т Т А G	A T C A T T G T A T A A T A C A A T A T C A T T G T A T A A T A C A A T		G T A C A T C A A A G G G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396824 B.US.1999.B_US_99_OP428_015_14228.EF396825	C G G A A G A A C T T A G	ATCATTGTATAATACAAT	A G C A A C T C T C T A T T G T	G T A C A T C A A A G G G T A C A T C A A A G G
B.US.1999.B_US_99_OP428_015_14228.EF396826 B.US.2000.B_US_00_OP428_039_05867.EF396827	C G G A A G A A C T T A G C G G A A G A A C T T A G	ATCATTGTATAATACAAT	A G C A A C T C T C T A T T G T	G T A C A T C A A A G G G T A C A T C A A G G G
B.US.2000.B_US_00_OP428_039_05867.EF396828	C G G A A G A A C T T A G C G G A A G A A C T T A G C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2000.B_US_00_OP428_039_05867.EF396829 B.US.2000.B_US_00_OP428_039_05867.EF396830	C G G A A G A A C T T A G C G G A A G A A C T T A G C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A A G G
B.US.2000.B_US_00_OP428_039_05867.EF396831	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A A G G
B.US.2000.B_US_00_OP428_039_05867.EF396832	C G G A A G A A C T T A G	A T C A T T G T A T A T A A T A C A A T		G T A C A T C A A G G G
B.US.2000.B_US_00_OP428_039_05867.EF396833 B.US.2000.B_US_00_OP428_039_05867.EF396834	C G G A A G A A C T T A G C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T A T C A T T G T A T A T A C A A T A T C A T T G T A T A T A C A A T	A G C A A C T C T C T A T T G T A G C A A <mark>C T C T C T C T A T T G</mark> T	G T A C A T C A A A G G G T A C A T C A A A G G
B.US.2000.B_US_00_OP428_039_05867.EF396835	С G G А А G А А C ТТА G	А Т С А Т Т G Т А Т А А Т А С А А Т	'	G T A C A T C A A G G G
B.US.2000.B_US_00_OP428_039_05867.EF396836	С G G А А G А А C ТТА G	А Т <mark>С А Т Т G Т А Т</mark> А А Т А <mark>С</mark> А А Т		G T A C A T C A A A G G G
B.US.2000.B_US_00_OP428_039_05867.EF396837 B.US.2000.B_US_00_OP428_039_05867.EF396838	С G G А А G А А C ТТА G С G G А А G А А C ТТА G	А Т С А Т Т Б Т А Т А А Т А С А А Т А Т <mark>С А Т Т Б Т А Т</mark> А А Т А <mark>С</mark> А А Т А Т <mark>С А Т Т Б Т А Т</mark> А А Т А <mark>С</mark> А А Т	: A	G T A C A T C A A A G G G T A C A T C A A A G G
B.US.2000.B_US_00_OP428_039_05867.EF396839 B.US.2000.B_US_00_OP428_039_05867.EF396840	C G G A A G A A C T T A G C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T A T C A T T G T A T A A T A C A A T A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T A G C A A C T C T C T A T T G T	G T A C A T C A A G G G G T A C A T C A A G G G
B.US.2000.B_US_00_OP428_063_13074.EF396841	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	' A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2000.B_US_00_OP428_063_13074.EF396842	C G G A A G A A C T T A G	A T C A T T G T T T A A T A C A A T	' A G C A A C T C T C T A T T G T	G T A C A T C A A A G G G
B.US.2000.B_US_00_OP428_063_13074.EF396843	C G G A A G A A C T T A G	A T C A T T A T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2000.B_US_00_OP428_063_13074.EF396844	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A <u>G</u> G G
B.US.2000.B_US_00_OP428_063_13074.EF396845	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	' A G C A A C T C T C T A T T G T	G T A C A T C A A A G G
B.US.2000.B_US_00_OP428_063_13074.EF396846	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	' A G C A A C T C T C T A T T G T	G T A C A T C A A A G G
B.US.2000.B_US_00_OP428_063_13074.EF396847	C G G A A G A A C T T A G	А Т С А Т Т С Т А Т А А Т А <mark>С</mark> А А Т	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2000.B_US_00_OP428_063_13074.EF396848	C G G A A G A A C T T A G	А Т С А Т Т С Т Т Т А А Т А С А А Т	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2000.B_US_00_OP428_063_13074.EF396849	C G G A A G A A C T T A G	А Т С А Т Т С Т А Т А А Т А <mark>С</mark> А А Т	A G C A A C T C T C T A T T G T	G T A C A T C A A A G G
B.US.2000.B_US_00_OP428_063_13074.EF396850	C G G A A G A A C T T A G	А Т С А Т Т С Т Т Т А А Т А С А А Т	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2000.B_US_00_OP428_063_13074.EF396851	C G G A A G A A <mark>C T T</mark> A G	А Т <mark>С А Т Т С Т <mark>С</mark> Т А А Т А <mark>С</mark> А А Т</mark>	A G C A A C T C T C T A T T G T	G T A <mark>C</mark> A T C A A G G G
B.US.2000.B_US_00_OP428_063_13074.EF396852	C G G A A G A A C T T A G	А Т С А Т Т С Т А Т А А Т А С А А Т	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2001.B_US_01_OP428_088_06550.EF396853	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2001.B_US_01_OP428_088_06550.EF396854	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2001.B_US_01_OP428_088_06550.EF396855	C G G A A G A A C T T A G	A T C A T T G T T T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2001.B_US_01_OP428_088_06550.EF396856	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2001.B_US_01_OP428_088_06550.EF396857	C G G A A G A A C T T A G	A T C A T T G T T T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2001.B_US_01_OP428_088_06550.EF396858	C G G A A G A A C T T A G	A T C A T T G T T T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2001.B_US_01_0P428_088_06550.EF396859	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2001.B_US_01_0P428_088_06550.EF396860	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2001.B_US_01_0P428_088_06550.EF396861	C G G A A G A A C T T A G	A T C A T T G T T T A A T A C A A T	A G C A A C T C T C T A T T G T	G T A C A T C A A G G G
B.US.2001.B_US_01_0P428_088_06550.EF396862	C G G A A G A A C T T A G	A T C A T T G T A T A A T A C A A T		G T A C A T C A A G G G
R HS 2001 R HS 01 OP428 088 06550 55206862		SLYNT	ΙΛΤΙ	R
(DP428		IAIL	\sim
		Г		G



Protein Feature Accent

See Protein Feature Accent Explanation for details. Return to input page.




Our Protein Feature Accent tool, loads a PDB 3D structure file and an alignment of protein sequences.

JMol is used to display the protein structure so you can rotate it, change the view from cartoon to spacefill, etc.

 Selecting sites or regions in the sequence

highlights that site or region in the structure.





Gag from all primate lentiviruses.

Looking outside the HIV-1 M group (roughly 100 years of evolution in humans) to SIVs representing at least 100,000 years and more likely over 5 million years of evolution.

Can help determine which amino acids are invariant and thus likely critical for protein function.



Thank you for attending!

- We are happy to help with research questions on the use of our tools and database.
- We are thrilled to get ideas for further tool development!

Contact us: <u>seq-info@lanl.gov</u> or <u>immuno@lanl.gov</u>



Datasets and programs

https://tinyurl.com/HIVDB-IEDB-2021

Aliview Bioedit Figtree

slides datafiles

